Press releases
Galenica continues to grow in 2024
Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 11 March 2025
With sales up 4.7% in the 2024 financial year, the Galenica Group grew strongly and generated consolidated net sales of CHF 3,921.1 million. As a result, Galenica outperformed market growth and gained market share in all its main business areas. Adjusted1 EBIT increased by 10.3% to CHF 211.0 million. Excluding the one-off special factors in the previous year, the adjusted1 operating result (EBIT) would have increased by 4.9%. Adjusted1 net profit from continuing operations also increased by 13.4% to CHF 183.2 million. Due to this positive result, the Board of Directors will propose to the Annual General Meeting that the dividend be raised to CHF 2.30 per share, which corresponds to an increase of 4.5%.
Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors
Press release, Thursday, 23 January 2025
Nadine Balkanyi-Nordmann, an experienced legal, compliance and governance expert, will be recommended for election as a member of the Board of Directors at the next Annual General Meeting of the Galenica Group.
Galenica reports strong sales growth once again
Ad hoc announcement pursuant to Art. 53 LR, Thursday, 23 January 2025
Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).